Current Report Filing (8-k)
January 11 2017 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
January
10, 2017
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-52138
|
20-2000871
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code
(250)
765-6424
N/A
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 3.02
Unregistered Sales of Equity Securities
On January 10, 2017 Lexaria Bioscience Corp. (the Company or
Lexaria) announced that it has received US$33,029.25
from the exercise
of stock options and warrants previously granted. The stock options were
exercised at prices from US$0.10 to US$0.2273 for a total of 151,500 common
shares being issued. The warrants were exercised at prices of US$0.15 and
US$0.14 for a total of 12,375 common shares being issued. All options and
warrants are being exercised by third parties who are neither officers nor
directors of the Company.
The Company has also issued 500,000 warrants to Correlation
Capital Inc, each warrant valid to purchase one restricted common share at a
price of US$0.44 for a period of one year.
No commissions or placement fees have been paid related to the
funds received from this warrant exercise. Proceeds raised are for general
corporate purposes.
- 2 -
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
Item 7.01 Regulation FD
Disclosure
A copy of the news release announcing that Lexaria has received
US$33,029.25
from the exercise of stock options and warrants previously
granted is filed as exhibit 99.1 to this current report and is hereby
incorporated by reference.
Item 9.01 Financial
Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
|
|
|
|
/s/ Chris
Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
Date: January 10,
2017
|
|
|
|